By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Relmada Therapeutics 



  New York    U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS








Company News
Relmada Therapeutics Appoints Dr. Maurizio Fava As Chair Of The Dextromethadone Scientific Advisory Board For Its Depression Program 6/28/2017 7:35:07 AM
Dr. Ottavio Vitolo Appointed Executive Clinical Advisor At Relmada Therapeutics 6/21/2017 8:26:22 AM
Charles J. Casamento Appointed Chairman Of Relmada Therapeutics Board Of Directors 6/15/2017 8:55:52 AM
Relmada Therapeutics Announces Settlement Of Legal Action With Laidlaw & Company 5/18/2017 6:58:42 AM
Relmada Therapeutics Announces FDA Fast Track Designation For D-Methadone For Adjunctive Treatment Of Major Depressive Disorder 4/13/2017 8:59:25 AM
Relmada Therapeutics Release: Announces FDA Acceptance Of IND And Authorization To Commence Phase 2a Clinical Trial For D-Methadone 1/26/2017 7:38:38 AM
Relmada Therapeutics Release: Pharma To Provide An Update On The Development Plan For LevoCap ER 1/25/2017 11:54:48 AM
Relmada Therapeutics Announces Issuance Of Key U.S. Patent Covering D-Methadone, An NMDA Receptor Antagonist, For The Treatment Of Depression And Other Psychiatric Symptoms 10/20/2016 9:56:24 AM
Relmada Therapeutics Announces Issuance Of Key U.S. Patent Covering D-Methadone, An NMDA Receptor Antagonist, For The Treatment Of Depression And Other Psychiatric Symptoms 10/19/2016 6:56:33 AM
Relmada Therapeutics To Present At The 15th Annual BIO Investor Forum 10/6/2016 9:30:42 AM
12345678910
//-->